Predictive Oncology’s (NASDAQ: POAI) Skyline Med
Post# of 281
(Total Views: 200)
Posted On: 11/25/2020 4:45:25 PM
Predictive Oncology’s (NASDAQ: POAI) Skyline Medical Sells 15 Streamway(R) Systems in Q3 2020 as COVID-era Drives Need for Sanitation Systems
- Closed design of Streamway(R) System provides safety from potential hazards of drips and spills during endoscopy, radiology, cystoscopy, urology procedures
- The Streamway(R) System reduces costs, minimizes environmental impact of 50 million potentially disease-infected canisters disposed into landfills
- POAI’s Skyline Medical sells 8 Streamway(R) Systems to large university hospital in Virginia, 15 sold halfway into Q3 2020
In the age of COVID-19, the need for sanitation and safety during hospital procedures has reached an all-time high. Health professionals have reported an inhibited level of performance due to a lack of protection, comfort, and increased fatigue during surgery (https://nnw.fm/pIvRU). Sanitary disposal systems, able to offer maximum protection to healthcare workers, have become incredibly necessary—and companies like Predictive Oncology are answering the call. Produced by Skyline Medical, a subsidiary of Predictive Oncology (NASDAQ: POAI), the patented Streamway(R) System features an entirely closed design, ensuring that medical professionals are safe from the potential hazards of drips and spills. It’s the first FDA-cleared direct-to-drain fluid disposal system that is designed specifically for medical applications such as endoscopy, radiology, cystoscopy and urology procedures.
The proprietary system automates the collection, measurement and disposal of potentially infectious waste that includes blood and irrigation fluids. By connecting directly to a facility’s plumbing system, the Streamway(R) System has the potential to change the way healthcare facilities manage fluid disposal by minimizing human intervention and increasing compliance with Occupational Safety and Health Administration (“OSHA”) and other regulatory agency safety guidelines.
Along with addressing safety concerns, the use of the Streamway(R) System reduces costs and minimizes environmental impacts by eliminating carts, evacuated bottles and the approximately 50 million potentially disease-infected canisters that go into landfills each year in the United States. COVID-era concerns have increased sales of the Streamway(R) System in 2020, with 15 sales in Q3 (including eight to a large university hospital organization in Virginia) in addition to sales throughout the world through direct sales and distributor partners.
Along with Skyline, POAI leverages the synergies of its other three wholly-owned subsidiaries – Helomics, TumorGenesis, and Soluble Biotech – to fulfill its mission of bringing precision medicine to the diagnosis of cancer. Besides the Streamway(R) System, POAI’s portfolio assets also include an AI-enhanced “smart” patient-derived tumor profiling platform, an in-house bioinformatics artificial intelligence (AI) platform, and a data-based approach to growing patient-specific tumors in a lab for the development of personalized treatment options.
The importance of precision medicine in cancer therapeutics has grown substantially, driven specifically by data-based predictive models of tumors and their responses to pharmaceutical treatments. Modeling various tumors can be both time and data-intensive, requiring five to seven years of clinical evaluation and observation to produce both historical and outcome data.
To that end, POAI has a significant competitive advantage through its vast collection of tumors and their related data, in addition to the company’s ability to access associated outcome data. The application of AI to its trove of more than 150,000 tumors assists oncologists in providing individualized patient treatments while driving forward the development of new targeted therapies in collaborations with pharmaceutical companies.
POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.
For more information, visit the company’s website at www.Predictive-Oncology.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Closed design of Streamway(R) System provides safety from potential hazards of drips and spills during endoscopy, radiology, cystoscopy, urology procedures
- The Streamway(R) System reduces costs, minimizes environmental impact of 50 million potentially disease-infected canisters disposed into landfills
- POAI’s Skyline Medical sells 8 Streamway(R) Systems to large university hospital in Virginia, 15 sold halfway into Q3 2020
In the age of COVID-19, the need for sanitation and safety during hospital procedures has reached an all-time high. Health professionals have reported an inhibited level of performance due to a lack of protection, comfort, and increased fatigue during surgery (https://nnw.fm/pIvRU). Sanitary disposal systems, able to offer maximum protection to healthcare workers, have become incredibly necessary—and companies like Predictive Oncology are answering the call. Produced by Skyline Medical, a subsidiary of Predictive Oncology (NASDAQ: POAI), the patented Streamway(R) System features an entirely closed design, ensuring that medical professionals are safe from the potential hazards of drips and spills. It’s the first FDA-cleared direct-to-drain fluid disposal system that is designed specifically for medical applications such as endoscopy, radiology, cystoscopy and urology procedures.
The proprietary system automates the collection, measurement and disposal of potentially infectious waste that includes blood and irrigation fluids. By connecting directly to a facility’s plumbing system, the Streamway(R) System has the potential to change the way healthcare facilities manage fluid disposal by minimizing human intervention and increasing compliance with Occupational Safety and Health Administration (“OSHA”) and other regulatory agency safety guidelines.
Along with addressing safety concerns, the use of the Streamway(R) System reduces costs and minimizes environmental impacts by eliminating carts, evacuated bottles and the approximately 50 million potentially disease-infected canisters that go into landfills each year in the United States. COVID-era concerns have increased sales of the Streamway(R) System in 2020, with 15 sales in Q3 (including eight to a large university hospital organization in Virginia) in addition to sales throughout the world through direct sales and distributor partners.
Along with Skyline, POAI leverages the synergies of its other three wholly-owned subsidiaries – Helomics, TumorGenesis, and Soluble Biotech – to fulfill its mission of bringing precision medicine to the diagnosis of cancer. Besides the Streamway(R) System, POAI’s portfolio assets also include an AI-enhanced “smart” patient-derived tumor profiling platform, an in-house bioinformatics artificial intelligence (AI) platform, and a data-based approach to growing patient-specific tumors in a lab for the development of personalized treatment options.
The importance of precision medicine in cancer therapeutics has grown substantially, driven specifically by data-based predictive models of tumors and their responses to pharmaceutical treatments. Modeling various tumors can be both time and data-intensive, requiring five to seven years of clinical evaluation and observation to produce both historical and outcome data.
To that end, POAI has a significant competitive advantage through its vast collection of tumors and their related data, in addition to the company’s ability to access associated outcome data. The application of AI to its trove of more than 150,000 tumors assists oncologists in providing individualized patient treatments while driving forward the development of new targeted therapies in collaborations with pharmaceutical companies.
POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.
For more information, visit the company’s website at www.Predictive-Oncology.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)